Diabetic Neuropathy Study Group: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study (vol 24, pg 1776, 2001)

被引：0
|
作者：
Hotta, N
Toyota, T
Matsuoka, K
Shigeta, Y
Kikkawa, R
Kaneko, T
Takahashi, A
Sugimura, K
Koike, Y
Ishii, J
Sakamoto, N
机构：
来源：
DIABETES CARE | 2002年 / 25卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：413 / 414
页数：2
相关论文
共 50 条
  • [21] GANGLIOSIDES IN THE TREATMENT OF DIABETIC NEUROPATHY - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY
    LINGETTI, M
    COTO, V
    RENGO, F
    SGAMBATO, S
    INNOCENTI, A
    FIORI, MG
    DIABETES NUTRITION & METABOLISM, 1992, 5 (04) : 275 - 282
  • [22] DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF HEPATOCYTE GROWTH FACTOR GENE THERAPY IN PAINFUL DIABETIC NEUROPATHY
    Ajroud-Driss, S.
    Vinik, A., I
    Smith, A. G.
    Cha, B-S
    Choi, S. H.
    Wymer, J. P.
    Shaibani, A.
    Kessler, J. A.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 94 - 94
  • [23] Double-Blind, Placebo-Controlled Study of Hepatocyte Growth Factor Gene Therapy in Painful Diabetic Neuropathy
    Ajroud-Driss, Senda
    Vinik, Aaron
    Smith, Gordon
    Cha, Bong-Soo
    Choi, Sung Hee
    Whymer, James
    Shaibani, Aziz
    Kessler, John A.
    ANNALS OF NEUROLOGY, 2015, 78 : S99 - S99
  • [24] A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety and Efficacy of NYX-2925 in Subjects with Painful Diabetic Peripheral Neuropathy
    Torri, S.
    Sainati, S.
    Burak, M.
    Hamilton, J.
    Katz, N.
    Madsen, T.
    JOURNAL OF PAIN, 2019, 20 (04): : S73 - S73
  • [25] Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy
    McDonnell, Aoibhinn
    Collins, Susie
    Ali, Zahid
    Iavarone, Laura
    Surujbally, Raulin
    Kirby, Simon
    Butt, Richard P.
    PAIN, 2018, 159 (08) : 1465 - 1476
  • [26] The effect of monochromatic infrared energy on sensation in subjects with diabetic peripheral neuropathy: A double-blind, placebo-controlled study - Response to Burke
    Clifft, JK
    Kasser, RJ
    Newton, TS
    Bush, AJ
    DIABETES CARE, 2006, 29 (05) : 1186 - 1187
  • [27] Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)
    Kharitonova, Tatiana
    Shvarts, Yury G.
    Verbovoy, Andrey F.
    Orlova, Natalia S.
    Puzyreva, Valentina P.
    Strokov, Igor A.
    BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (03)
  • [28] A randomized, double-blind, placebo-controlled study of histone deacetylase type 6 inhibition for the treatment of painful diabetic peripheral neuropathy
    Michelson, David
    Chin, William W.
    Dworkin, Robert H.
    Freeman, Roy
    Herrmann, David N.
    Mazitschek, Ralph
    Pop-Busui, Rodica
    Shaibani, Aziz
    Vornov, James
    Jones, Melissa
    Jarpe, Matthew
    Hader, Brittany
    Viera, Theresa
    Hylan, Michelle
    Kachmar, Tim
    Jones, Simon
    PAIN REPORTS, 2023, 8 (06) : E1114
  • [29] A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of lacosamide in subjects with painful distal diabetic neuropathy
    Wymer, J
    Garrison, C
    Simpson, J
    Koch, B
    NEUROLOGY, 2006, 66 (05) : A202 - A202
  • [30] Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial
    Arezzo, Joseph C.
    Rosenstock, Julio
    LaMoreaux, Linda
    Pauer, Lynne
    BMC NEUROLOGY, 2008, 8 (1)
12345